710 Medtronic Parkway, NE
Medtronic, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
Founders: Earl Bakken and Palmer Hermundlie
CEO: Omar Ishrak
CFO: Karen Parkhill
CSO (Scientific): Richard Kuntz
Please click here for Medtronic job opportunities.
Tweets by Medtronic
2110 articles with Medtronic
Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease
Medtronic plc announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com.
2018 Integrated Performance Report Shows Improvement on Environmental Stewardship and Diversity Aspirational Goals
Medtronic Begins Renal Denervation Study for High Blood Pressure Patients Prescribed Anti-Hypertensive Medication
FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension
Medtronic Presents IN.PACT SFA Trial Five-Year Data and Total IN.PACT All-Subjects Analysis in VIVA Late Breaking Clinical Trials
New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD
FDA Approves New SynchroMed(TM) II myPTM(TM) Personal Therapy Manager That Enables Patients to Alleviate Unpredictable Pain
myPTM Allows Patients to Personalize Their Treatment by Delivering On-Demand Boluses, or Drug Doses, Within Therapeutic Limits Set by Their Physician
Next-Generation Thoracic Endovascular Repair (TEVAR) Device Expands Applicability to Broader Range of Patients
Medtronic plc announced today that its co-founder, Earl E. Bakken, passed away peacefully on October 21, 2018 at his home on Kiholo Bay on the Big Island of Hawaii. He was 94 years old.
Medtronic Launches the Control Workflow(SM) to Help Eliminate Oral Opioids and Provide Effective Pain Relief
For Use with SynchroMed(TM) II Intrathecal Drug Delivery System, the Control WorkflowAims to Effectively Address Chronic Pain Without the Use of Oral Opioids
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
System is Fully Integrated with Medtronic's Market-Leading Imaging and Navigation Technology to Transform Posterior Cervical Spine Surgery
The global MRI-guided neurosurgical ablation market is projected to expand at a CAGR of 4.9% during the forecast period 2018–2028 and reach US$ 216.3 Mn by the end of 2028.
A commercially-available medical device developed by Medtronic is helping paralyzed patients walk again.The device, which stimulates the spinal cord through electrical pulses, has been successful in helping some individuals who lost the ability to walk through injuries to their spine, regain the ...
Medtronic Builds on TAVR Clinical Evidence Portfolio with Five-Year CoreValve Durability Data and Complete Two-Year Outcomes in Intermediate Risk Aortic Stenosis Patients
TCT18: New Five-Year Data with CoreValve TAVR System Suggests Durability Over Time, While Complete Results from the SURTAVI Trial Show Benefits of TAVR in Intermediate Risk Patients
Late-Breaking Clinical Study Results Demonstrate Exceptional Safety and Efficacy Outcomes for Resolute Onyx(TM) DES
TCT18: BIONYX Study Shows Strong Performance with Durable Polymer Resolute Onyx DES in Head-to-Head Comparison with Biodegradable Polymer DES
Medtronic Presents IN.PACT Global Study Three-Year Data and Total IN.PACT(TM) Imaging and Propensity Analyses
Clinical Evidence Shared at TCT and CIRSE Reaffirm IN.PACT(TM) Admiral(TM) Drug-Coated Balloon as a Primary Therapy to Treat Complex, Real-World Patient Populations
Acquisition to Accelerate Medtronic's Strategy to Transform Spinal Procedures and Improve Outcomes Through Fully-Integrated Surgical Solutions
Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves
Medtronic Receives FDA Approval for Revised TAVR Labeling and Begins Investigational Study of Low Risk Patients with Bicuspid Valves
Medtronic Joins Catalyst CEO Champions For Change and Pledges to Accelerate Women Into Management and Board Seats
Medtronic CEO Omar Ishrak Commits to Continue Accelerating Diversity, Inclusion and Gender Equality
Company Marks its Eleventh Consecutive Year on the North American Dow Jones Sustainability Index (DJSI)